Drug Profile
Uzansertib - Incyte Corporation
Alternative Names: INCB-053914; INCB-53914; Pan-PIM kinase inhibitor - Incyte CorporationLatest Information Update: 14 Dec 2021
Price :
$50
*
At a glance
- Originator Incyte Corporation
- Class Antineoplastics; Cyclopentanes; Piperidines; Pyridines; Small molecules
- Mechanism of Action PIM3 protein inhibitors; Proto oncogene proteins c pim 1 inhibitors; Proto-oncogene protein pim-2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Acute myeloid leukaemia; Diffuse large B cell lymphoma; Multiple myeloma; Myelofibrosis; Solid tumours
Most Recent Events
- 14 Dec 2021 Discontinued - Phase-I for Diffuse large B cell lymphoma (Combination therapy, Recurrent) in USA (unspecified route) (Incyte Corporation pipeline, December 2021)
- 14 Dec 2021 Discontinued - Phase-I/II for Solid tumours (Combination therapy, Late-stage disease, Second-line therapy or greater) in USA (PO) (Incyte Corporation pipeline, December 2021)
- 14 Dec 2021 Discontinued - Phase-I/II for Solid tumours (Late-stage disease, Monotherapy, Second-line therapy or greater) in USA (PO) (Incyte Corporation pipeline, December 2021)